VNDA
Vanda Pharmaceuticals Inc (VNDA)
Healthcare • NASDAQ • $6.28-1.72%
- Symbol
- VNDA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $6.28
- Daily Change
- -1.72%
- Market Cap
- $377.65M
- Trailing P/E
- N/A
- Forward P/E
- 31.40
- 52W High
- $9.94
- 52W Low
- $3.81
- Analyst Target
- $15.50
- Dividend Yield
- N/A
- Beta
- 0.65
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the trea…
Company websiteResearch VNDA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.